$5.57
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?
Overview
52-week range
$3.71
$11
26% of range
Avg surprise (last 3)
+21.7%
Avg reaction (last 2)
-2.6%
50% positive
Latest IV / EM
104%
EM ±23.8% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.54 | $-0.55 | +1.8% | -980.0% | +2.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.33 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.52 | $-0.70 | +25.7% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.05 | $-0.08 | +37.5% | — | -7.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.46 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.50 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.61 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.13 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.29 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.34 | -$0.52 | +34.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-8M | — | $-7M | $-7M | $-8M | — | $-6M | $-7M |
| Net income | $-13M | — | $-6M | $-6M | $570,000 | — | $-4M | $10M |
| EPS (diluted) | $-0.54 | — | $-0.33 | $-0.52 | $-0.50 | — | $-0.46 | $-1.50 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $37M | $29M | $43M | $22M | $20M | $26M | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $64M | $49M | $50M | $30M | $27M | $31M | $38M | $44M |
| Total assets | $64M | $49M | $51M | $30M | $28M | $32M | $39M | $45M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $27M | $19M | $13M | $14M | $17M | $24M | $11M | $13M |
| Total equity | $38M | $30M | $37M | $16M | $11M | $7M | $-28M | $-15M |